Table 2 Trial adherence and use of lipid-modifying medication post-trial
Time | Treatment | Proportion on-treatment (%) | |
|---|---|---|---|
Fenofibrate group | Placebo group | ||
Year 1 | Fenofibrate/placebo | 91.4 | 91.2 |
Simvastatin | 94.5 | 95.5 | |
Year 2 | Fenofibrate/placebo | 88.8 | 91.5 |
Simvastatin | 93.6 | 96.1 | |
Year 3 | Fenofibrate/placebo | 87.2 | 90.2 |
Simvastatin | 91.3 | 92.9 | |
Year 4 | Fenofibrate/placebo | 85.3 | 86.3 |
Simvastatin | 92.9 | 92.5 | |
Trial exit visit | Fenofibrate/placebo | 82.7 | 86.3 |
Simvastatin | 93.1 | 91.0 | |
1st post-trial visit | Fibrate | 7.2 | 7.4 |
Stains | 77.1 | 78.4 | |
Last post-trial visit | Fibrate | 5.4 | 4.8 |
Stains | 72.0 | 74.0 | |